McKesson (MCK) AI Stock Analysis

Company Guidance

For fiscal 27, McKesson raised adjusted earnings per diluted share guidance to $45.60 to $46.40, implying adjusted EPS growth of 17% to 19%, or 19% to 21% excluding the impact of the Norway divestiture and the net gains within the U.S. Oncology Network in fiscal 2026, versus a long term growth target of 13% to 16%; revenue growth is anticipated at 6% to 10% and operating profit growth at 12% to 16%. North American pharmaceutical revenue growth is anticipated at 5% to 9% and operating profit growth at 14% to 18%; oncology and multispecialty revenue growth at 20% to 24% and operating profit growth at 18% to 22%, or 22% to 26% excluding the net gains of $51 million in fiscal 2026; prescription technology solutions revenue growth at 2.5% to 6.5% and operating profit growth at 11% to 15%; and MedSurg revenue growth at 1% to 6% with operating profit to range from a 4% decline to flat. Corporate expenses are anticipated at the high end of the $580 million to $640 million range, interest expense at the high end of $380 million to $420 million, income attributable to noncontrolling interest at $290 million to $320 million, and the full year effective tax rate at 18% to 19%; free cash flow is anticipated at approximately $4.5 billion to $4.9 billion, approximately $5 billion of shares are expected to be repurchased during fiscal 27, and diluted weighted average shares outstanding are estimated to be in the range of 115.5 million to 117.5 million.